Insulet Corporation
$193.4
▲
0.55%
2026-04-22 10:12:13
www.insulet.com
NMS: PODD
Explore Insulet Corporation stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$13.48 B
Current Price
$193.4
52W High / Low
$354.88 / $194.61
Stock P/E
55.6
Book Value
$21.53
Dividend Yield
—
ROCE
18.87%
ROE
18.12%
Face Value
—
EPS
$3.48
Exp Qtr EPS
—
Sector
Healthcare
Industry
Medical Devices
Employees
5,400
Beta
1.47
Debt / Equity
66.18
Current Ratio
2.81
Quick Ratio
2.15
Forward P/E
24.37
Price / Sales
5.12
Enterprise Value
$14.15 B
EV / EBITDA
25.08
EV / Revenue
5.22
Rating
Strong Buy
Target Price
$340.26
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Short-term liquidity looks comfortable.
- Strong operating margin profile.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | LivaNova PLC | $65.81 | — | $3.6 B | — | 11.09% | -19.24% | $71.92 / $34 | $21.96 |
| 2. | Sensus Healthcare, Inc. | $4.06 | — | $66.84 M | — | -21.33% | -14.85% | $5.92 / $3.03 | $1.57 |
| 3. | ClearPoint Neuro, Inc. | $11.16 | — | $349.74 M | — | -27.78% | -95.64% | $30.1 / $8.27 | $0.95 |
| 4. | GE HealthCare Technologies Inc. | $71.58 | 15.76 | $32.85 B | 0.19% | 9.93% | 22.38% | $89.77 / $59.95 | $22.77 |
| 5. | Myomo, Inc. | $0.9 | — | $34.65 M | — | -47.54% | -86.24% | $4.99 / $0.6 | $0.3 |
| 6. | AdaptHealth Corp. | $12.67 | — | $1.72 B | — | 5.17% | -4.25% | $12.87 / $7.11 | $11.46 |
| 7. | Cytek Biosciences, Inc. | $4.57 | — | $592.62 M | — | -10.52% | -18.05% | $6.18 / $2.37 | $2.66 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 783.8 M | 706.3 M | 649.1 M | 569 M | 597.5 M | — |
| Operating Profit | 146.3 M | 117.7 M | 121.1 M | 88.8 M | 109.3 M | — |
| Net Profit | 101.6 M | 87.6 M | 22.5 M | 35.4 M | 100.7 M | — |
| EPS in Rs | 1.47 | 1.26 | 0.32 | 0.51 | 1.45 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.71 B | 2.07 B | 1.7 B | 1.31 B |
| Operating Profit | 473.8 M | 308.9 M | 220.1 M | 37.6 M |
| Net Profit | 247.1 M | 418.3 M | 206.3 M | 4.6 M |
| EPS in Rs | 3.57 | 6.04 | 2.98 | 0.07 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.19 B | 3.09 B | 2.59 B | 2.25 B |
| Total Liabilities | 1.68 B | 1.88 B | 1.86 B | 1.77 B |
| Equity | 1.52 B | 1.21 B | 732.7 M | 476.4 M |
| Current Assets | 1.91 B | 1.89 B | 1.58 B | 1.31 B |
| Current Liabilities | 680.1 M | 528.4 M | 451.2 M | 364.7 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 569.3 M | 430.2 M | 145.7 M | 119 M |
| Investing CF | -222.7 M | -146.2 M | -119.4 M | -191.1 M |
| Financing CF | -595.3 M | -28 M | -13.6 M | -40.3 M |
| Free CF | 349.9 M | 296.2 M | 36.5 M | -38.3 M |
| Capex | -219.4 M | -134 M | -109.2 M | -157.3 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 22.07% | 30.02% | — | — |
| Earnings Growth % | 102.76% | 4384.78% | — | — |
| Profit Margin % | 20.19% | 12.16% | 0.35% | — |
| Operating Margin % | 14.91% | 12.97% | 2.88% | — |
| Gross Margin % | 69.79% | 68.35% | 61.72% | — |
| EBITDA Margin % | 20.45% | 19.07% | 8.35% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.